{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:10:24Z","timestamp":1791508224868,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40801-023-00386-y","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T20:39:46Z","timestamp":1693946386000},"page":"557-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of Pancreatitis Among Patients with Inflammatory Bowel Disease Treated with Vedolizumab: Observation from a Large Global Safety Database"],"prefix":"10.1007","volume":"10","author":[{"given":"Joe F.","family":"Wernicke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Verstak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Spalding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Ademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"1","key":"386_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"GBD 2017 Inflammatory Bowel Disease Collaborators","year":"2020","unstructured":"GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10114","key":"386_CR2","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u201378.","journal-title":"Lancet"},{"issue":"3","key":"386_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384\u2013413.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"386_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000506364","volume":"101","author":"MC Sulz","year":"2020","unstructured":"Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F, Swiss IBDnet an official working group of the Swiss Society of Gastroenterology. Treatment algorithms for Crohn\u2019s disease. Digestion. 2020;101(Suppl 1):43\u201357.","journal-title":"Digestion"},{"issue":"1","key":"386_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"386_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14(1):4\u201322.","journal-title":"J Crohns Colitis"},{"key":"386_CR7","volume-title":"Entyvio (Vedolizumab) prescribing information","author":"Takeda Pharmaceuticals USA, Inc.","year":"2021","unstructured":"Takeda Pharmaceuticals USA, Inc. Entyvio (Vedolizumab) prescribing information. Lexington: Takeda Pharmaceuticals USA, Inc.; 2021."},{"key":"386_CR8","volume-title":"Entyvio INN-Vedolizumab summary of product characteristics","author":"Takeda Pharma A\/S","year":"2021","unstructured":"Takeda Pharma A\/S. Entyvio INN-Vedolizumab summary of product characteristics. Vallensbaek: Takeda Pharma A\/S; 2021."},{"issue":"12","key":"386_CR9","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437\u201344.","journal-title":"J Crohns Colitis"},{"issue":"8","key":"386_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel J-F, Sandborn WJ, GEMINI 1 Study Group, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"8","key":"386_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel J-F, Sands BE, GEMINI 2 Study Group, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"386_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/apt.16060","volume":"52","author":"EV Loftus Jr","year":"2020","unstructured":"Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353\u201365.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"386_CR13","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982\u201392.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"386_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ecco-jcc\/jjv153","volume":"10","author":"LR Ramos","year":"2016","unstructured":"Ramos LR, Sachar DB, DiMaio CJ, Colombel J-F, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis. 2016;10(1):95\u2013104.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"386_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.4291\/wjgp.v7.i3.276","volume":"15","author":"F Antonini","year":"2016","unstructured":"Antonini F, Pezzilli R, Angelelli L, Macarri G. Pancreatic disorders in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2016;15(7):276\u201382.","journal-title":"World J Gastrointest Pathophysiol."},{"issue":"9","key":"386_CR16","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/MPA.0000000000001650","volume":"49","author":"B T\u00e9l","year":"2020","unstructured":"T\u00e9l B, Stubnya B, Gede N, Varj\u00fa P, Kiss Z, M\u00e1rta K, et al. Inflammatory bowel diseases elevate the risk of developing acute pancreatitis: a meta-analysis. Pancreas. 2020;49(9):1174\u201381.","journal-title":"Pancreas"},{"issue":"3","key":"386_CR17","first-page":"A08190427","volume":"67","author":"JE Pedersen","year":"2020","unstructured":"Pedersen JE, \u00c4ngquist LH, Jensen CB, Kj\u00e6rgaard JS, Jess T, Allin KH. Risk of pancreatitis in patients with inflammatory bowel disease\u2014a meta-analysis. Dan Med J. 2020;67(3):A08190427.","journal-title":"Dan Med J"},{"issue":"2","key":"386_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000499138","volume":"35","author":"FU Weiss","year":"2019","unstructured":"Weiss FU, Laemmerhirt F, Lerch MM. Etiology and risk factors of acute and chronic pancreatitis. Visc Med. 2019;35(2):73\u201381.","journal-title":"Visc Med."},{"issue":"2","key":"386_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pan.2017.01.005","volume":"17","author":"SE Roberts","year":"2017","unstructured":"Roberts SE, Morrison-Rees S, John A, Williams JG, Brown TH, Samuel DG. The incidence and aetiology of acute pancreatitis across Europe. Pancreatology. 2017;17(2):155\u201365.","journal-title":"Pancreatology"},{"issue":"7","key":"386_CR20","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1053\/j.gastro.2018.11.081","volume":"156","author":"J Mayerle","year":"2019","unstructured":"Mayerle J, Sendler M, Hegyi E, Beyer G, Lerch MM, Sahin-T\u00f3th M. Genetics, cell biology, and pathophysiology of pancreatitis. Gastroenterology. 2019;156(7):1951\u201368.","journal-title":"Gastroenterology"},{"key":"386_CR21","doi-asserted-by":"publisher","first-page":"bcr2017222554","DOI":"10.1136\/bcr-2017-222554","volume":"2018","author":"S Picardo","year":"2018","unstructured":"Picardo S, So K, Venugopal K, Chin M. Vedolizumab-induced acute pancreatitis: the first reported clinical case. BMJ Case Rep. 2018;2018:bcr2017222554.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"386_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/ecco-jcc\/jjx167","volume":"12","author":"RN Lopez","year":"2018","unstructured":"Lopez RN, Gupta N, Lemberg DA. Vedolizumab-associated pancreatitis in paediatric ulcerative colitits: functional selectivity of the \u03b14\u03b27 integrin and MAdCAM-1 pathway? J Crohns Colitis. 2018;12(4):507\u20138.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"386_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa042","volume":"26","author":"E Lin","year":"2020","unstructured":"Lin E, Katz S. Acute pancreatitis in a patient with ulcerative colitis on vedolizumab. Inflamm Bowel Dis. 2020;26(5): e44.","journal-title":"Inflamm Bowel Dis"},{"issue":"9573","key":"386_CR24","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641\u201357.","journal-title":"Lancet"},{"issue":"4","key":"386_CR25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cgh.2019.07.022","volume":"18","author":"GR Lichtenstein","year":"2020","unstructured":"Lichtenstein GR, Shahabi A, Seabury SA, Lakdawalla DN, Espinosa OD, Green S, et al. Lifetime economic burden of Crohn\u2019s disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18(4):889\u201397.e10.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"386_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3904\/kjim.2020.505","volume":"36","author":"A Richardson","year":"2021","unstructured":"Richardson A, Park WG. Acute pancreatitis and diabetes mellitus: a review. Korean J Intern Med. 2021;36(1):15\u201324.","journal-title":"Korean J Intern Med"},{"issue":"10","key":"386_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2165\/00002018-200831100-00002","volume":"31","author":"AR Balani","year":"2008","unstructured":"Balani AR, Grendell JH. Drug-induced pancreatitis: incidence, management and prevention. Drug Saf. 2008;31(10):823\u201337.","journal-title":"Drug Saf"},{"issue":"5","key":"386_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"J-F Colombel","year":"2017","unstructured":"Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"1","key":"386_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1177\/2050640620966513","volume":"9","author":"SS Olesen","year":"2021","unstructured":"Olesen SS, Mortensen LH, Zinck E, Becker U, Drewes AM, N\u00f8jgaard C, et al. Time trends in incidence and prevalence of chronic pancreatitis: a 25-year population-based nationwide study. United Eur Gastroenterol J. 2021;9(1):82\u201390.","journal-title":"United Eur Gastroenterol J."},{"issue":"10","key":"386_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.14740\/jocmr3561w","volume":"10","author":"FS Fousekis","year":"2018","unstructured":"Fousekis FS, Theopistos VI, Katsanos KH, Christodoulou DK. Pancreatic involvement in inflammatory bowel disease: a review. J Clin Med Res. 2018;10(10):743\u201351.","journal-title":"J Clin Med Res"},{"issue":"10","key":"386_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185193","volume":"12","author":"S Fagagnini","year":"2017","unstructured":"Fagagnini S, Heinrich H, Rossel J-B, Biedermann L, Frei P, Zeitz J, et al. Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS ONE. 2017;12(10): e0185193.","journal-title":"PLoS ONE"},{"issue":"44","key":"386_CR32","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.3748\/wjg.v12.i44.7197","volume":"12","author":"SI Gan","year":"2006","unstructured":"Gan SI, Edwards AL, Symonds CJ, Beck PL. Hypertriglyceridemia-induced pancreatitis: a case-based review. World J Gastroenterol. 2006;12(44):7197\u2013202.","journal-title":"World J Gastroenterol"},{"issue":"8","key":"386_CR33","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1111\/j.1572-0241.1999.01287.x","volume":"94","author":"M Barthet","year":"1999","unstructured":"Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94(8):2141\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"386_CR34","first-page":"124","volume":"32","author":"A Mertz","year":"2019","unstructured":"Mertz A, Nguyen NA, Katsanos KH, Kwok RM. Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann Gastroenterol. 2019;32(2):124\u201333.","journal-title":"Ann Gastroenterol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00386-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T23:07:04Z","timestamp":1703027224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["386"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00386-y","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"8 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"JFW, TV, TZ, and WS are employees of Takeda and hold stock\/stock options in Takeda. LL was a fellow of Takeda at the time of the analyses. YC and AA were interns of Takeda at the time of the analyses.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets, including the redacted study protocol, redacted statistical analysis plan, and individual participants\u2019 data supporting the results reported in this article, will be made available within 3 months from initial request to researchers who provide a methodologically sound proposal. The data will be provided after its de-identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization. Data are available upon request via application at .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable because data are from a global safety database that contains spontaneous post-marketing reports from patients and healthcare professionals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JFW and TV were responsible for the study design, implementation, and data extraction. TZ and YC conducted the statistical analysis. All authors were involved in interpreting the results, contributed to the preparation of this manuscript, and read and revised each draft. All authors have read and approved the final manuscript for submission and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}